HSCT Treatment
Feb 16, 2026
Alternative Therapeutic Strategies Beyond HSCT: Reimagining Curative Options in Hematologic Disease
Summary HSCT is a potentially curative treatment for hematologic malignancies (acute leukemias, lymphomas, multiple myeloma) and bone marrow failure syndromes. In 2025, approximately 26,000 HSCT cases were reported in the 7MM, with Multiple Myeloma/Plasma Cell Dyscrasias having the largest patient pool in th...
Read More...
Jan 05, 2026
FDA Approves Omeros’ YARTEMLEA: A Breakthrough for Stem Cell Transplant Patients Facing TA-TMA
The FDA has approved YARTEMLEA (narsoplimab-wuug), marking a watershed moment in hematopoietic stem cell transplantation (HSCT) medicine. Omeros Corporation's therapeutic advance represents the first and only FDA-approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
